Oppenheimer assumed coverage on shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) in a research report released on Tuesday, BenzingaRatingsTable reports. The brokerage issued an outperform rating and a $14.00 price target on the biotechnology company’s stock.

A number of other research firms also recently issued reports on AUPH. HC Wainwright reissued a buy rating and set a $25.00 price target on shares of Aurinia Pharmaceuticals in a research report on Tuesday, June 4th. BidaskClub downgraded Aurinia Pharmaceuticals from a hold rating to a sell rating in a research report on Thursday, September 5th. Zacks Investment Research downgraded Aurinia Pharmaceuticals from a buy rating to a hold rating in a research report on Tuesday, July 16th. Citigroup assumed coverage on Aurinia Pharmaceuticals in a research report on Monday. They set an outperform rating and a $14.00 price target on the stock. Finally, Royal Bank of Canada reissued a buy rating and set a $11.00 price target on shares of Aurinia Pharmaceuticals in a research report on Thursday, August 8th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Aurinia Pharmaceuticals has a consensus rating of Buy and a consensus target price of $15.18.

AUPH opened at $6.45 on Tuesday. Aurinia Pharmaceuticals has a 12-month low of $5.06 and a 12-month high of $7.85. The business’s fifty day simple moving average is $5.92 and its 200-day simple moving average is $6.29. The company has a market capitalization of $600.57 million, a price-to-earnings ratio of -8.49 and a beta of 1.12.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). Aurinia Pharmaceuticals had a negative return on equity of 50.08% and a negative net margin of 13,231.97%. The firm had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.05 million. On average, equities analysts forecast that Aurinia Pharmaceuticals will post -0.68 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Victory Capital Management Inc. purchased a new stake in shares of Aurinia Pharmaceuticals during the 1st quarter worth $45,000. Toronto Dominion Bank lifted its stake in shares of Aurinia Pharmaceuticals by 64.7% during the 1st quarter. Toronto Dominion Bank now owns 9,780 shares of the biotechnology company’s stock worth $63,000 after purchasing an additional 3,842 shares during the last quarter. Spark Investment Management LLC purchased a new stake in shares of Aurinia Pharmaceuticals during the 1st quarter worth $71,000. UBS Asset Management Americas Inc. purchased a new stake in shares of Aurinia Pharmaceuticals during the 2nd quarter worth $88,000. Finally, A.R.T. Advisors LLC lifted its stake in shares of Aurinia Pharmaceuticals by 44.9% during the 2nd quarter. A.R.T. Advisors LLC now owns 18,395 shares of the biotechnology company’s stock worth $121,000 after purchasing an additional 5,700 shares during the last quarter. Hedge funds and other institutional investors own 31.96% of the company’s stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.

Featured Story: What are momentum indicators and what do they show?

Analyst Recommendations for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.